Key result
Novel apical devices aim to transform transapical mitral interventions into reproducible percutaneous procedures.
Transapical access is highlighted as an optimal route for transcatheter mitral valve interventions, with ongoing development needed for percutaneous closure devices.
Answers are grounded in this paper and cite their sources.
Transapical access may warrant consideration for mitral interventions; leaves open dedicated percutaneous closure device trials.
TA access will play a vital role in the expansion of transcatheter valve therapy in the treatment of mitral valve pathology. The short distance from the apex to the mitral valve annulus and the ability to accommodate large caliber sheaths make the apex the optimal access point. The continued development of apical access and closure devices will eventually produce a percutaneous device with a small “footprint” which provides a reliable hemostatic seal and does not impact ventricular function.
No takes yet. Share an insight, caveat, or question.
Leshnower et al. (2015) conducted a review in Mitral valve pathology. Ventricular apical access and closure devices was evaluated. Novel ventricular apical access and closure devices are being developed to transform transapical access into a more reproducible, percutaneous procedure for transcatheter mitral valve interventions.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: